Roche told investors on Monday that it plans to make significant cuts to both the cost and time it takes for it to develop new drugs, including its slate of experimental weight loss and diabetes medications.

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a growing number say they’re open to covering GLP-1 drugs, they’re still in the minority. Some 62% of the firms surveyed said they are “not likely” to begin coverage in the coming year.

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the medications in their health insurance plans, a new survey shows. In a report published Wednesday in the journal Health Affairs,